%D9%8A%D9%81%D9%88%D9%84%D9%88%D9%83%D9%88%D9%85%D8%A7%D8%A8%D0%95%D0%B2%D0%BE%D0%BB%D0%BE%D0%BA%D1%83%D0%BC%D0%B0%D0%B1EvolocumabEvolocumabEvolocumab%C3%89volocumab%D7%90%D7%95%D7%95%D7%9C%D7%95%D7%A7%D7%95%D7%9E%D7%91Evolocumab%E3%82%A8%E3%83%9C%E3%83%AD%E3%82%AF%E3%83%9E%E3%83%96EwolokumabEvolocumabQ15623825
about
P3781
Evolocumab in Acute Coronary SyndromeOpen Label Study of Long Term Evaluation Against LDL-C TrialEffect of Evolocumab on Vascular FunctionEffect of Evolocumab on Coronary Endothelial FunctionEvolocumab Versus LDL Apheresis in Patients With HypercholesterolemiaSafety and Tolerability of Repatha in Indian Subjects With Homozygous Familial HypercholesterolemiaEffects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European CountriesEXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 TrialEffects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial DysbetalipoproteinemiaEffect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass SurgeryEVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF PilotSafety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed DyslipidemiaChart Review of Repatha® in Subjects With HyperlipidaemiaEffect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial DiseaseSubclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®Early Treatment With Evolocumab in Patients With ST-elevation Myocardial InfarctionStudy to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 InhibitorsImpact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing CoronarographyCHOlesterol Lowering and Residual Risk in Type 2 DiabetesEvolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients
P4844
Q62818300-D8AC17BF-9601-422F-872E-A72E1678CF9BQ63322603-C1DEFBB3-070C-484E-96F9-4491B8E05E0EQ63393606-D2591343-FDBF-44CA-8B40-40A303A5A227Q63399307-2BAF56BE-39A8-48DE-87BF-C1E5B5CCFE9EQ63404381-114F6C92-5734-43BA-B7FB-96E40638D463Q63405228-6F964F82-D7BA-4440-9733-A04AC52D5FC2Q63571201-0A30D638-C01A-4433-B8C0-0213043C72EBQ63576617-6C74CE78-A2EA-4789-9A9F-B0EA881D3CEEQ63576767-5A6F2D08-E0D9-40F5-AAF0-00E88A29CB1BQ63583396-DE7ECED0-8842-49E0-946B-F97BE510F35AQ63587126-BCBEB4FE-055E-43F4-9C53-BB0EB2F4DE0FQ63594671-B58C2932-8EB7-4BC2-8232-F295610B9DA1Q63613502-591B3C4E-6E99-41F5-8A5C-3A5F4E9ACA72Q63813295-90FE86C5-4239-456A-ABBC-E7E35427EE32Q87930781-819D0683-4D2A-47B5-8D8D-59EEC645A87EQ87930866-DE6D0B14-5760-429D-A8AE-77CBCF3B66F8Q87931168-8170443E-1371-4C94-82F5-95FDFFC14E17Q87931457-86C8B8A8-2C3F-4896-9018-1B678F511C5FQ89155135-287C145B-BF05-4AAC-9463-806F3B0B7D06Q90693444-108C8F1C-E06B-4160-A747-4EB0B92DD017Q93215097-C3D63B17-70B8-4E6B-B7F6-B144A8E14CE4Q95056543-4D10B53C-45C0-4CD6-AE0E-DB8580FDBC20
P4844
description
Antikörper
@de
chemická sloučenina
@cs
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
name
Evolocumab
@de
Evolocumab
@en
Evolocumab
@es
Evolocumab
@vi
Ewolokumab
@pl
evolocumab
@it
evolokumab
@nn
évolocumab
@fr
Еволокумаб
@bg
אוולוקומב
@he
type
label
Evolocumab
@de
Evolocumab
@en
Evolocumab
@es
Evolocumab
@vi
Ewolokumab
@pl
evolocumab
@it
evolokumab
@nn
évolocumab
@fr
Еволокумаб
@bg
אוולוקומב
@he
altLabel
AMG-145
@en
prefLabel
Evolocumab
@de
Evolocumab
@en
Evolocumab
@es
Evolocumab
@vi
Ewolokumab
@pl
evolocumab
@it
evolokumab
@nn
évolocumab
@fr
Еволокумаб
@bg
אוולוקומב
@he
P2175
P31
P486
P592
P6366
P1705
Evolocumab
@en
P176
P2115
N0000192016
P2175
P2275
Evolocumab
@en
P231
1256937-27-5
P267
P3345
P3780
P486
P592
CHEMBL2364655
P6366
2778114629
P652
LKC0U3A8NJ